GlassScriptPhysician profile
Kanti Devkota
NPI 1063979003
$250.27
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $60.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.35 | 2021 | |
| Astellas Pharma US INC | $30.65 | 2021-2022 | |
| Inari Medical, INC. | $28.72 | 2022 | |
| Lilly USA, LLC | $26.17 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.12 | 2021 | |
| Abbvie INC. | $19.78 | 2021 | |
| Glaxosmithkline, LLC. | $18.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.26 | 2021 | |
| Amgen INC. | $11.90 | 2021 | |
| Pfizer INC. | $11.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanti Devkota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.